Skip to content
Clioquinol
Nystaform (clioquinol) is a small molecule pharmaceutical. Clioquinol was first approved as Nystaform on 1982-01-01. It is used to treat acneiform eruptions, dermatitis, folliculitis, lichenoid eruptions, and tinea pedis in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
skin and connective tissue diseasesD017437
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Clioquinol
+
Nystatin
Tradename
Company
Number
Date
Products
NYSTAFORMBayerN-050235 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
dermoscribe ichybumOTC monograph not final2019-03-04
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
acneiform eruptionsEFO_1000662D017486—
dermatitisHP_0011123D003872L30.9
folliculitis—D005499—
lichenoid eruptions—D017512—
tinea pedisEFO_0007512D014008B35.3
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D08: Antiseptics and disinfectants
— D08A: Antiseptics and disinfectants
— D08AH: Quinoline derivatives, antiseptics and disinfectants
— D08AH30: Clioquinol
— D09: Medicated dressings
— D09A: Medicated dressings
— D09AA: Medicated dressings with antiinfectives
— D09AA10: Clioquinol
G: Genito urinary system and sex hormones
— G01: Gynecological antiinfectives and antiseptics
— G01A: Antiinfectives and antiseptics, excl. combinations with corticosteroids
— G01AC: Quinoline gynecological antiinfectives
— G01AC02: Clioquinol
P: Antiparasitic products, insecticides and repellents
— P01: Antiprotozoals
— P01A: Agents against amoebiasis and other protozoal diseases
— P01AA: Hydroxyquinoline derivatives for amoebiasis and other protozoal diseases
— P01AA02: Clioquinol
— P01AA52: Clioquinol, combinations
S: Sensory organ drugs
— S02: Otologicals
— S02A: Antiinfective drugs, otologic
— S02AA: Antiinfectives
— S02AA05: Clioquinol
HCPCS
No data
Clinical
Clinical Trials
1 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chest painD002637HP_0100749R07.9————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCLIOQUINOL
INNclioquinol
Description
5-chloro-7-iodoquinolin-8-ol is a monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by chlorine and iodine, respectively. It has antibacterial and atifungal properties, and is used in creams for the treatment of skin infections. It has also been investigated as a chelator of copper and zinc ions for the possible treatment of Alzheimer's disease. It has a role as an antifungal agent, an antineoplastic agent, an antimicrobial agent, an antibacterial agent, a chelator, an antiprotozoal drug and a copper chelator. It is an organochlorine compound, an organoiodine compound and a monohydroxyquinoline.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Oc1c(I)cc(Cl)c2cccnc12
Identifiers
PDB—
CAS-ID130-26-7
RxCUI5942
ChEMBL IDCHEMBL497
ChEBI ID74460
PubChem CID2788
DrugBankDB04815
UNII ID7BHQ856EJ5 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,938 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
29,690 adverse events reported
View more details